Twist Bioscience Stock

Twist Bioscience ROE

The Return on Equity (ROE) of Twist Bioscience (TWST) as of Aug 16, 2026 is -16.42 %. In the previous year, Return on Equity (ROE) was -44.16 % — a change of -62.81% (higher).

ROE

-16.42 %

YoY

-62.81%

Last updated:

In 2026, Twist Bioscience's return on equity (ROE) was -16.42 %, a -62.81% increase from the -44.16 % ROE in the previous year.

Access this data via the Eulerpool API

Twist Bioscience Stock analysis

What does Twist Bioscience do? Twist Bioscience Corp is a company specializing in the production and applications of synthetic DNA. It was founded in 2013 and is based in San Francisco, California, USA. The company utilizes proprietary technologies to cost-effectively produce high-quality and high-quantity synthetic DNA. The company operates in three business areas: DNA synthesis, biopharmaceuticals, and data storage. The DNA synthesis division is the core of the company and involves the production of synthetic DNA for applications in various industries, including medicine, agricultural science, biotechnology, plastic engineering, and others. The company manufactures customized DNA synthesis products tailored to the needs of its customers, allowing them to accelerate and optimize their research and development projects. Twist Bioscience has also developed a proprietary technology called "Twist Biosensor" that enables rapid and cost-effective analysis of genetic variations. The biopharmaceutical division focuses on the development of therapeutics and diagnostics based on synthetic DNA. Twist Bioscience develops antibodies and proteins that can be used in cancer and immunotherapy, as well as diagnostics. In the data storage field, Twist Bioscience develops solutions for storing large amounts of data on DNA. This technology utilizes the dense and stable structure of DNA to securely and reliably store data in the long term. Twist Bioscience's DNA synthesis products are utilized by researchers, companies, and public institutions in various industries. Customers value not only the wide product portfolio but also the high quality and precision of the products, as well as the speed of order processing. The company operates a number of manufacturing facilities near its customers in Europe and Asia to ensure fast and efficient delivery of its products. This allows Twist Bioscience to have a strong position in the global market. In recent years, the company has achieved significant milestones. In 2018, Twist Bioscience went public and raised a total of $70 million through its IPO. The company has also established partnerships with various other companies and institutions to develop new applications and products. Overall, Twist Bioscience is a growing company specializing in the production and applications of synthetic DNA. With its wide range of high-quality and customized DNA synthesis products, as well as its innovative solutions in the biopharmaceutical and data storage sectors, the company has established a strong market position. Twist Bioscience is one of the most popular companies on Eulerpool.

ROE Details

Decoding Twist Bioscience's Return on Equity (ROE)

Twist Bioscience's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Twist Bioscience's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Twist Bioscience's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Twist Bioscience’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Twist Bioscience stock

Return on Equity (ROE) of Twist Bioscience is -16.42 % in 2026.

Return on Equity (ROE) of Twist Bioscience changed from -44.16 % to -16.42 %, representing a -62.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Twist Bioscience since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Twist Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Twist Bioscience

All Key Metrics — Twist Bioscience